ArticleHuman vaccines & immunotherapeutics2016
Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Intravenous anti-P. aeruginosa IgY antibodies increase bacterial concentration in porcine septic shock with bacteremia.Intensive care medicine experimental · 2026Article
- Exploring the Antimicrobial and Immunomodulatory Potential of Gecko-Derived Cathelicidin Gj-CATH5.Biomolecules · 2025Article
- Immune system dynamics in response to Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2025Review
- A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade.Antibody therapeutics · 2025Review
- Evaluation of specific chicken IgY antibody value developing diagnostic capture antibody ELISA kit against Foot and Mouth disease.Archives of Razi Institute · 2024Article
- IgY antibodies: The promising potential to overcome antibiotic resistance.Frontiers in immunology · 2023Review
- IgYs: on her majesty's secret service.Frontiers in immunology · 2023Review
- Overcoming Barriers to Preventing and TreatingBiomedicines · 2022Review
- Intravenous anti-Innate immunity · 2022Article
- Immune Response to Biofilm Growing PulmonaryBiomedicines · 2022Review
- Chicken IgY reduces the risk ofFrontiers in microbiology · 2022Article
- Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection.Scientific reports · 2021Article
- Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.Frontiers in immunology · 2021Review
- Immune Responses toFrontiers in immunology · 2021Review
- IgY - turning the page toward passive immunization in COVID-19 infection (Review).Experimental and therapeutic medicine · 2020Review
- Immunotherapy with IgY Antibodies toward Outer Membrane Protein F Protects Burned Mice againstJournal of immunology research · 2020Article
- Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review.International immunopharmacology · 2019Review
- Inhalation of specific anti-Pseudomonas aeruginosa IgY antibodies transiently decreases P. aeruginosa colonization of the airway in mechanically ventilated piglets.Intensive care medicine experimental · 2019Article
- IgY antibodies for the immunoprophylaxis and therapy of respiratory infections.Human vaccines & immunotherapeutics · 2019Review
- Anti-lipopolysaccharide egg yolk antibodies enhance the phagocytosis of mammalian phagocytes.Biology open · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moderation of polymorphonuclear neutrophils (PMNs) as part of a critical defense against invading pathogens may offer a promising therapeutic approach to supplement the antibiotic eradication of Pseudomonas aeruginosa infection in non-chronically infected cystic fibrosis (CF) patients. We have observed that egg yolk antibodies (IgY) harvested from White leghorn chickens that target P. aeruginosa opsonize the pathogen and enhance the PMN-mediated respiratory burst and subsequent bacterial killing in vitro. The effects on PMN phagocytic activity were observed in different Pseudomonas aeruginosa strains, including clinical isolates from non-chronically infected CF patients. Thus, oral prophylaxis with anti-Pseudomonas aeruginosa IgY may boost the innate immunity against Pseudomonas aeruginosa in the CF setting by facilitating a rapid and prompt bacterial clearance by PMNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.